Search Within

Shigeaki Umeda

Formats
  1. Journal Article (4)
  2. Meeting Abstract (3)
  3. Editorial (1)
Groups
  1. Center for Molecular Imaging and Biotechnology (CMIB) (8)
  2. Center for Pancreatic Cancer Research (8)
  3. Department of Pathology and Laboratory Medicine (8)
  4. GSK Faculty (8)
  5. Human Oncology and Pathogenesis Program (8)
  6. Sloan Kettering Institute Postdocs (8)

More Groups

People
  1. Christine Iacobuzio-Donahue (8)
  2. Wungki Park (5)
  3. Dana Pe'er (4)
  4. Akimasa Hayashi (3)
  5. Anna Varghese (3)
  6. Catherine O'Connor (3)

More People

Years
  1. 2024 (2)
  2. 2023 (3)
  3. 2022 (3)
Publications
  1. Annals of Oncology (1)
  2. Cancer Discovery (1)
  3. Cancer Research (1)
  4. Clinical Cancer Research (1)
  5. Journal of Clinical Oncology (1)
  6. Nature (1)

More Publications

Publishers
  1. American Association for Cancer Research (3)
  2. Nature Publishing Group (3)
  3. American Society of Clinical Oncology (1)
  4. Oxford University Press (1)

Results (8)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II trial of Pembrolizumab and OLApaRib (POLAR) maintenance for select patients (pts) with metastatic pancreatic cancer (mPC) with (A) homologous recombination deficiency (HRD), (B) non-core HRD (ncHRD) and (C) exceptional response to platinum
    Meeting Abstract

    Park, W.; O'Connor, C.; Chou, J.; Schwartz, C.; Larsen, M.; Varghese, A.; Yu, K.; Balogun, F.; Yang, J.; Katz, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A targetable secreted neural protein drives pancreatic cancer metastatic colonization and HIF1α nuclear retention
    Journal Article

    Yamaguchi, N.; Wu, Y. G.; Ravetch, E.; Takahashi, M.; Khan, A. G.; Hayashi, A.; Mei, W.; Hsu, D.; Umeda, S.; de Stanchina, E.; more...
    Cancer Discovery (2024)

    Fulltext@MSK | Save
  • Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): Two cohorts B non-core homologous recombination deficiency (HRD) and C exceptional response to platinum-therapy
    Meeting Abstract

    Park, W.; O'Connor, C.; Chou, J. F.; Schwartz, C.; Varghese, A. M.; Larsen, M.; Balogun, F.; Brenner, R.; Yu, K. H.; Diguglielmo, E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • STING inhibits the reactivation of dormant metastasis in lung adenocarcinoma
    Journal Article

    Hu, J.; Sánchez-Rivera, F. J.; Wang, Z.; Johnson, G. N.; Ho, Y. J.; Ganesh, K.; Umeda, S.; Gan, S.; Mujal, A. M.; Delconte, R. B.; more...
    Nature (2023)

    Fulltext@MSK | Save
  • Application of high-throughput single-nucleus DNA sequencing in pancreatic cancer
    Journal Article

    Zhang, H.; Karnoub, E. R.; Umeda, S.; Chaligné, R.; Masilionis, I.; McIntyre, C. A.; Sashittal, P.; Hayashi, A.; Zucker, A.; Mullen, K.; more...
    Nature Communications (2023)

    Fulltext@MSK | Save
  • Optimal tumor metastatic gene programs in pancreatic cancer
    Meeting Abstract

    Jiménez-Sánchez, A.; Xie, Y.; Sharma, R.; Chu, T. Y.; Liu, V.; Park, W.; Hayashi, A.; Umeda, S.; Mazutis, L.; Nawy, T.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Clinico-genomic characterization of ATM and HRD in pancreas cancer: Application for practice
    Journal Article

    Park, W.; O'Connor, C. A.; Bandlamudi, C.; Forman, D.; Chou, J. F.; Umeda, S.; Reyngold, M.; Varghese, A. M.; Keane, F.; Balogun, F.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • MITI minimum information guidelines for highly multiplexed tissue images
    Editorial

    Schapiro, D.; Yapp, C.; Sokolov, A.; Reynolds, S. M.; Chen, Y. A.; Sudar, D.; Xie, Y.; Muhlich, J.; Arias-Camison, R.; Arena, S.; more...
    Nature Methods (2022)

    Fulltext@MSK | Save